Biotech Values

[apljack]

OK, so I can tell you that for my procedure codes, the last year saw nominal cuts; there was a real dollar decrease for several of the codes.

On the other point in my previous point (re: medicare not paying for mistakes) our local business section ran an article today about the unintended consequences for this ruling, namely that defensive medicine will increase, the number of diagnostic tests for patients will increase and the burden on medicare will increase. I'm sure that these changes are not what the brains behind this move had in mind, but it will keep me busy as hell (I evaluate dementia and risk for assessing need of level of patient supervision.)

It would also be an area for value investing as the need to identify pre-existing infection will skyrocket for patient admissions. I knw that RPBIF is working on a rapid infection panel test, but I'm sure there are better investment opportunities out there. Any suggestions?


aj